The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
December 8th 2024
A propensity score-matched study from ASH 2024 suggests GLP-1 RA use reduced VTE risk in type 2 diabetes.
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Prepregnancy Cardiovascular Risk Factors Play Role in Risk of Adverse Maternal, Fetal Outcomes
July 22nd 2021Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.
More Than A Heart and Lungs in The Chest, with Paul Thompson, MD
July 22nd 2021In his most recent column, Dr. Paul Thompson offers perspective on why he feels clinicians should consider performing a chest x-ray in patients with dyspnea or frequent palpitations, but no history of lung disease and a normal cardiac work-up.
Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds
July 20th 2021A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.
Abelacimab Demonstrates Potential of Factor XI Inhibition in Preventing Blood Clots
July 19th 2021A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.
Roxadustat Receives Negative Vote from FDA Panel Ahead of PDUFA Date
July 19th 2021The FDA's CRDAC July 15 meeting concluded with committee members voting against recommending the approval of roxadustat for the treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis.
FDA Panel Votes Against Roxadustat, Cites Risk of Thrombotic Events
July 16th 2021The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.